Organisation paid for research Program year 2025 Source: CMS Open Payments

Southeast Retina Center PC

Neither a doctor nor a teaching hospital

Research payments

$7,738,643

647 payments

Through program year 2025, Southeast Retina Center PC is reported as receiving $7,738,643 in research payments, across 647 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,214,504	278
2024	Research	$850,333	81
2023	Research	$684,661	53
2022	Research	$966,458	60
2021	Research	$1,729,552	82
2020	Research	$1,163,338	57
2019	Research	$1,129,796	36

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $5,563,666 269 payments
Regeneron Pharmaceuticals, Inc. $1,254,286 226 payments
Ocular Therapeutix, Inc. $564,180 35 payments
Apellis Pharmaceuticals, Inc. $137,157 52 payments
Topcon Corporation $87,872 2 payments
Hoffmann-La Roche Limited $40,946 3 payments
Roche TCRC, Inc. $34,430 4 payments
Astellas Pharma Global Development $17,930 6 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $13,053 41 payments
AbbVie, Inc. $11,719 2 payments

Studies the money was for Research payments · program years 2019–2025

Study of the Port Delivery System With Ranibizumab in Patients With Diabetic MacUlar Edema $1,644,508 37 payments
Port Delivery System for Ranibizumab $723,154 23 payments
Va2 Phiii Rhine $682,401 17 payments
Port Delivery System of Ranibizumab Extension Study $545,966 29 payments
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration $531,786 30 payments
Iamd Observational Study $456,659 33 payments
Endolaserless Vitrectomy With Intravitreal Aflibercept Injection for Proliferative Diabetic Retinopathy-Related Vitreous Hemorrhage (Laser Less Trial) $449,787 10 payments
A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema $373,462 176 payments
Endolaserless Vitrectomy With Intravitreal Aflibercept Injection for Proliferative Diabetic Retinopathy-Related Vitreous Hemorrhage Laser Less Trial $314,830 2 payments
Va2 Phiii $273,112 13 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.